COST PER RESPONDER OF LIXISENATIDE VERSUS RAPID-ACTING INSULIN INTENSIFICATION REGIMENS IN AN INSULIN-EXPOSED TYPE 2 DIABETES MELLITUS (T2DM) POPULATION

Author(s)

Afonso M¹, Ryan F², Pitcher A², Lew E¹
¹Sanofi, Chilly-Mazarin, France, ²IMS Health, London, UK

Presentation Documents

PDB36--strong-u-afonso-m-u-sup-1-sup-strong-ryan-f-sup-2-sup-pitcher-a-sup-2-sup-lew-e-sup-1-sup-br-sup-1-sup-sanofi-chilly-mazarin-france-sup-2-sup-ims-health-london-uk

OBJECTIVES: Lixisenatide on top of insulin glargine +/- metformin has been shown to reduce HbA1c while showing lower symptomatic hypoglycaemic events and weight benefit in the treatment of T2DM when compared to rapid-acting insulin intensification regimens (GetGoal Duo2;NCT01768559). The objective of this study was to determine the cost per responder of lixisenatide compared to insulin glulisine once (QD) or three times daily (TID) in UK, Spain and Italy. METHODS: Patients had confirmed T2DM insufficiently controlled with insulin glargine +/- metformin. Efficacy and safety outcomes came from GetGoal Duo2, a 26-week phase 3 trial comparing lixisenatide versus insulin glulisine QD and TID. Response was defined as a patient achieving HbA1c

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PDB36

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Diabetes/Endocrine/Metabolic Disorders

Explore Related HEOR by Topic

Economic Evaluation

Presentation